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Abstract 44 
Context: Anabolic hormones are important factors in maintaining muscle mass for ageing 45 
men, but their role in overall motor unit structure and function is unclear.  46 
Objective: To determine associations of anabolic and reproductive hormone levels with 47 
motor unit characteristics in quadriceps muscle in older healthy and frail men.  48 
Design: Observational cohort study of community dwelling men. 49 
Participants: Healthy and frail men > 65 years old. 50 
Intervention: None. 51 
Outcome measure: Quantitative assessments of electromyography-derived motor unit 52 
potential size (MUP) and compound muscle action potential size (CMAP) of vastus 53 
lateralis muscle.  54 
Results: We studied 98 men (mean±SD: age 73±6 years; BMI 25.7±4.0 kg/m2; diabetes 55 
11%) of whom 45% were prefrail and 18% frail. After adjusting for age, BMI and 56 
prevalent diabetes, higher total and free testosterone levels were significantly related to 57 
larger CMAP (total testosterone: β (95% CI): 0.3 (0.08, 0.53); free testosterone: 0.34 (0.13, 58 
0.56)). Exploratory analysis showed the relationship between free testosterone and 59 
CMAP was stronger in frail rather than robust men. In univariate analyses, estradiol was 60 
associated with CMAP size (0.37 (0.16, 0.57)); and vitamin D was associated with MUP 61 
size (0.22 (0.01, 0.43)) but these relationships were no longer significant after adjusting 62 
for potential confounders.  63 
Conclusion: Our data highlight the associations between androgen levels and the 64 
electrophysiological characteristics of older men, particularly in the frail. Clinical trials 65 
involving administration of androgens will help to elucidate the potential benefits of 66 






Adverse outcomes associated with frailty, including reduced mobility and falls, might be 70 
linked to underlying sarcopenia, characterized by low muscle mass and related physical 71 
dysfunction. Lower cross sectional area and total number of muscle fibers, both features 72 
of sarcopenia, have been linked with impaired anabolic signalling, increased levels of pro-73 
inflammatory cytokines and declining numbers of motor units(1–4). Whilst anabolic 74 
hormones are considered key factors in maintaining muscle fiber cross sectional area 75 
through the effects on muscle protein turnover, their role in the broader neuromuscular 76 
system, including motor unit structure and function, during healthy ageing and frailty is 77 
less clear.  78 
A motor unit includes a single alpha motor neuron and all the skeletal muscle 79 
fibers it innervates. Activation of individual motor units during movements ensures the 80 
precise matching of muscle forces to meet the task requirements. Various methods of 81 
electromyography (EMG) have been utilised to study human motor unit (MU) 82 
characteristics. Intramuscular EMG (iEMG) employing needle electrodes is able to 83 
provide detailed information on the structure and function of MUs via the measurement 84 
of consecutive action potentials during voluntary contractions in a ‘localized’ fashion (5–85 
7). Similarly, involuntary electrically stimulated contractions provide a more ‘global’ view 86 
of the electrophysiological characteristics of muscle via skin surface measures(8).  87 
The declining numbers of motor units with advancing age(9,10) may cause 88 
denervation of muscle fibers and constrain the ability of the central nervous system to 89 
control voluntary movements. By way of compensation to preserve muscle function, some 90 
denervated fibers can be reinnervated by axonal branching from neighbouring motor 91 
neurons(11). This remodelling process leads to an increase in the size of surviving motor 92 
units in older adults compared with young, but contributes to fiber atrophy and fiber 93 
losses when reinnervation fails(12)(13). The underlying regulation of motor unit 94 
remodelling in sarcopenia and frailty remains poorly understood, but may be associated 95 
with hormonal changes during ageing, particularly declines in anabolic hormone levels. 96 
The neuromuscular protective effects of androgens have been studied in animal 97 
models in which male castration led to motor unit dendrites’ atrophy, which was reversed 98 
by testosterone administration(14,15). Similarly, when compared with controls, 99 
testosterone therapy attenuated atrophy of motor neuron dendrites and muscle fibers in 100 
female rats with spinal cord injury(16). Exogenous testosterone accelerated regeneration 101 
of facial(17) and sciatic nerves(18) post injury and in humans, testosterone treatment 102 




recent studies, however, suggest that dihydrotestosterone might be a more potent 104 
anabolic hormone in mammalian skeletal muscle, exerting effects on force in slow and 105 
fast twitch fibres alike(20).  Dehydroepiandrosterone sulphate (DHEA-S) is a weak 106 
androgen with neuroprotective and anti-apoptotic properties, which are independent of 107 
any anabolic effects exerted after conversion to testosterone. Both in vivo and in vitro 108 
models suggest that DHEA-S promotes neurogenesis, neuronal survival, and prevents 109 
neurotoxicity due to its anti-glucocorticoid effects(21). None of these properties, 110 
however, have been studied in the context of the peripheral nervous system and motor 111 
neuron preservation in humans.  112 
Similarly, cumulative evidence indicates that estradiol has a neuroprotective role 113 
in the central nervous system(22). However, animal and human research also suggests 114 
neuroprotective effects of estradiol on spinal motoneurons, where the Akt anti-apoptotic 115 
signalling pathway is regulated by estradiol(23,24).  116 
The anabolic role of vitamin D in the muscle has previously been studied in 117 
health, sarcopenia and frailty predominantly in the context of muscle protein 118 
turnover(25,26). Despite the fact that low levels of vitamin D have been linked to 119 
impaired balance and frequent falls, no studies to date have investigated whether vitamin 120 
D levels are related to neuronal control of muscle function and motor unit health.  121 
Given the possible roles of these anabolic factors for human neuromuscular 122 
function and the lack of data at the whole motor unit level in healthy ageing and frailty, 123 
we aimed to determine the association between anabolic hormone levels and motor unit 124 
characteristics in quadriceps muscles in older men from the general population. 125 
 126 
Subjects and methods 127 
Participants 128 
A total of 114 men aged 65-90 years were recruited from the Greater Manchester area 129 
between 2014-2017. Participants were recruited from local universities’ databases, 130 
National Health Service general practices and secondary care, including outpatient 131 
departments, day hospitals and community physiotherapy centres. All participants 132 
provided written informed consent. The study was also open to the general public 133 
through poster and newspaper advertisements. A full list of the selection criteria is 134 
included in the Supplemental Material(27).  135 
Ethical approval for the study was obtained from the National Research Ethics 136 




Assessments  138 
Questionnaires  139 
Each participant provided details of lifestyle, medical history and medications taken. The 140 
men also completed the Geriatric Depression Scale questionnaire (GDS)(28) and the 141 
Physical Activity Scale for the Elderly (PASE) questionnaire(29). 142 
 143 
Anthropometry measures 144 
Body mass (kg) and height (m) were measured and total body composition assessed by 145 
dual-energy X-ray absorptiometry (DXA) (Lunar Prodigy Advance, version EnCore 146 
10.50.086). Appendicular lean mass with appendicular bone mineral content (BMC) 147 
removed was normalized to height to establish sarcopenia status(12). Appendicular lean 148 
mass strongly correlates with total body lean mass in our unpublished data of 168 older 149 
males (r = 0.88, p<0.001). 150 
Assessment of physical function, activity and frailty 151 
Physical function was assessed objectively by Short Physical Performance Battery testing 152 
which included assessment of four-meter walking speed, standing balance and 5 chair 153 
stands. The “Timed up and go” (TUG) was also performed, where participants were 154 
invited to stand from a seated position and walk 3 meters forward around a cone as 155 
quickly as possible, returning to their original seating position. Time from the command 156 
“Go” until the participant returned to their original seated position was recorded.  157 
Grip strength was measured using a handgrip dynamometer (JAMAR).  158 
Participants were invited to squeeze the handle as hard as possible for around 3 seconds 159 
and the maximum contraction force (in kg) was recorded. This was repeated 2 times for 160 
each hand, alternating between the right and left with 30 seconds rest between trials. 161 
Maximal voluntary isometric contraction of the knee extensors was assessed with the 162 
participants leg fastened to a force transducer 30cm below the centre of the knee joint, 163 
with hips and knees flexed at 900. Participants performed a standardised warm-up of 164 
several contractions, after which they were asked to perform a maximal effort which 165 
lasted approximately 2-3 seconds. This was repeated a further two times separated by 166 
short rest intervals, and the highest of the values was accepted as the MVC. 167 
Frailty was characterized by the two commonly used approaches: the frailty 168 
phenotype (FP) and frailty index (FI). Frailty phenotype was adapted from the 169 
Cardiovascular Health Study (CHS) based on five criteria: sarcopenia, exhaustion, 170 




population-specific cut-off points are presented in the Supplemental Table 1, alongside 172 
the original CHS criteria(27). Individuals with one or more of these criteria were classed 173 
as frail and those with none were classed as robust. 174 
The FI is comprised of 37 health deficits (symptoms and signs, functional impairments), 175 
which are known to accumulate with age and are associated with adverse health 176 
outcomes. The FI was created using a standardized procedure(31). Continuous variables 177 
were dichotomized based on the distribution of participants’ scores; cut-off points were 178 
set at the worst performing 10th centile. Individuals with over 20% of missing data on 179 
relevant deficits were excluded from the analysis. The details of the variables used to 180 
create an FI and specific cut-off points are described in Supplemental Table 2(27). 181 
 182 
Hormone measurements 183 
A fasting venous blood sample was used for all hormone measurements. All samples were 184 
collected between 08:30 – 09:30 AM. A validated liquid chromatography-mass 185 
spectrometry system was used to analyze total testosterone (T, intra- and interassay 186 
coefficients of variation (CVs): 1.4% and 8.3%), estradiol (E2; CVs: 5.4% and 3.1%), 187 
dihydrotestosterone (DHT; CVs: 8.3%) vitamin D (CVs: 6.2% and 5.1%) and DHEA-S (CVs: 188 
1.9% and 3.1%). Free T (fT) levels were derived from total T, SHBG (analyzed using 189 
chemiluminescence), and albumin (measured by bromcresol purple) concentrations 190 
using Vermeulen’s formula(32). 191 
  192 
Electromyography 193 
The EMG data were collected from around the motor point of the vastus lateralis (VL). 194 
The parameters of interest were the supramaximal compound muscle action potential 195 
(CMAP) and motor unit potential (MUP). 196 
The CMAP represents the sum of the electrophysiological signal from all motor 197 
units detectable by the recording electrode when simultaneously activated at the same 198 
time using supramaximal stimulation of the peripheral nerve. It has been used clinically 199 
to track disease progression in spinal muscular atrophy and amyotrophic lateral 200 
sclerosis(33,34). The CMAP was recorded at the VL motor point by surface EMG after 201 
percutaneous femoral nerve stimulation.  202 
Motor unit potential (MUP) represent the sum of electrophysiological signals as 203 
action potentials propagate along the sarcolemma of individual muscle fibers of a single 204 




into the VL muscle at the motor point to a depth of ∼1–2 cm. The participant then 206 
performed a sustained voluntary isometric contraction at 25% of their maximal effort and 207 
held it for 12–15 s. In between contractions, the needle was repositioned using 208 
combinations of 180 degrees needle rotations and needle withdrawals of ∼5 mm to 209 
obtain a minimum of six recordings from spatially distinct areas. The details of the EMG 210 
technique used, data recording and analysis are described in the Supplemental 211 
Material(27).  212 
Statistical analysis 213 
 214 
Descriptive statistics are presented as the mean ± standard deviation (SD) or n (%), and 215 
statistical significance of between-group differences was assessed using analysis of 216 
variance. 217 
Linear regression models determined relationships between predictors 218 
(hormone level) and outcome (MUP or CMAP). Each predictor as well as CMAP was 219 
considered as an untransformed value standardized as a Z score [(raw score – 220 
mean)/standard deviation] to allow comparison of results between predictors. Motor 221 
unit potential area, in view of significant skewing, was log-transformed before being 222 
standardized as Z score to meet the linear regression assumptions. 223 
Models were adjusted for age, body mass index (BMI), diabetes and alcohol excess 224 
as these correlated with the predictors and therefore were potential confounders. The 225 
analyses where estradiol was a predictor were further adjusted for total testosterone - 226 
the main precursor of E2 production in men. The results of these analyses were displayed 227 
as standardized coefficients (beta) with 95% confidence intervals.  228 
In an exploratory analysis, we introduced an interaction term (hormone x frailty 229 
phenotype or hormone x frailty index) as well as a FP or FI variable, as appropriate, to the 230 
fully adjusted models to assess whether the relationships between hormone levels and 231 
EMG parameter values varies in health in relation to the level of frailty.  232 
All analyses were performed using STATA 13 SE software (StataCorp. 2013. Stata 233 
Statistical Software: Release 13. College Station, TX: StataCorp LP). 234 
 235 
Results 236 
Out of 114 men who participated in the study, 98 men had complete data on MUP and 237 
CMAP and were included in the analysis. The mean age of men was 73 years and mean 238 




more than 14 units of alcohol per week. Cardiovascular disease was present in 19% of 240 
participants and diabetes in 11%.  241 
We assessed relationships between hormone predictors and clinical variables (age, BMI, 242 
diabetes, smoking and alcohol excess) that could potentially confound relationships 243 
between hormone levels and EMG parameters (Table 2). 244 
These data indicated that age, BMI, diabetes and alcohol excess might be potential 245 
confounders and therefore we included these as covariates in subsequent models. 246 
In unadjusted analysis T, free T, DHT and E2 were positively related to CMAP size: 247 
one standard deviation (SD) higher level of T, free T, DHT and E2 were associated with 248 
larger CMAPs normalized as standard deviation units [total T: β (95% CI): 0.48 (0.29, 249 
0.68); free T: 0.48 (0.29, 0.67); DHT: 0.37 (0.16, 0.57); E2: 0.37 (0.16, 0.57)]. After 250 
adjusting for age, BMI, alcohol excess and prevalent diabetes, only total and free T 251 
remained significantly related to CMAP (Table 3). 252 
In unadjusted analysis one SD higher level of free T and vitamin D was associated 253 
with larger mean MUP. However, these associations were no longer statistically 254 
significant after BMI adjustment (Table 3).  255 
Exploratory analysis suggested the relationship between free T and CMAP was much 256 
stronger in frail men compared to the robust ((β (95%CI): 0.82 (0.05, 1.60), p for 257 
interaction of 0.038)), as assessed by frailty phenotype (Figure 1).  258 
The relationship between free T and CMAP was greater with increasing frailty 259 
levels as assessed by the frailty index ((β (95%CI): 1.54 (0.02, 3.06), p for interaction of 260 
0.047; Figure 2)).  261 
This secondary analysis also suggested a positive relationship between DHEA-S 262 
and CMAP in prefrail ((β (95%CI): 0.58 (0.15, 1.00), p=0.009 for interaction) and frail men 263 
(β (95%CI): 0.54 (0.03, 1.05), p=0.039 for interaction); Figure 3)).  264 
When we explored associations between physical function and EMG parameters, 265 
Timed up and go (TUG) was negatively related to MUP size, and the association was 266 
partially attenuated after adjusting for lean muscle mass in keeping with a partial 267 
mediation model (Supplemental Table 3)(27). TUG was negatively linked with CMAP and 268 
the associations appeared largely independent of lean muscle mass (Supplemental Table 269 
3)(27). Knee extensor maximum voluntary contraction (KEMVC) was associated with 270 
MUP size and this association appeared to be explained by lean muscle mass 271 
(Supplemental Table 3)(27). We did not observe a significant relationship between knee 272 
extensor MVC and CMAP. 273 
Finally, we performed an analysis assessing the potential influence of selection 274 




98 men in the study cohort were less likely to be frail and were less likely to have 276 
sarcopenia, weakness, respiratory disease, diabetes and arthritis (Supplemental Table 277 
4)(27). Therefore, the strength of relationships described above may be conservative 278 




Main findings 283 
Our study presents several novel findings: Firstly, testosterone levels were positively 284 
associated with skeletal muscle electrophysiological characteristics as assessed by CMAP 285 
in unadjusted models and also models adjusted for BMI, age and prevalent diabetes.  We 286 
have also observed a similar trend for DHT, however adjustment for diabetes attenuated 287 
the DHT-CMAP relationship. Secondly, we showed that estradiol was related to muscle 288 
CMAP, but this relationship was rendered non-significant after adjusting for total 289 
testosterone levels indicating that the effect is likely to be testosterone-related. Thirdly, 290 
we showed that vitamin D was positively related to motor unit potential size in 291 
unadjusted models, but this effect was no longer significant after adjusting for BMI. 292 
Finally, the significance of free T and DHEA-S relationships with muscle contractility 293 
(assessed by CMAP) appeared to be greater in frail men. These novel human observations 294 
may have important implications for future clinical research and clinical care. 295 
 296 
Prior studies and mechanistic insights 297 
Data from our previous work, and that from other groups, indicate that muscle strength 298 
and the number of motor units declines progressively from old (˜66yrs) to very old 299 
(˜82yrs)(35) age and that CMAP and MUP size differ according to sarcopenic and frailty 300 
status(12,36).  301 
Whilst these past studies demonstrate important links between motor units, 302 
muscle function and health status in older age, they do not provide more detailed 303 
underpinning mechanisms that may identify causes of motor unit changes with advancing 304 
age. The pathophysiological mechanisms linking neuromuscular health with frailty in 305 
humans remain largely unknown. Although our study is the first to investigate 306 
associations between hormone levels and motor unit function of older adults, others have 307 




anabolic hormones occurring in parallel with development of physical impairments, 309 
sarcopenia and frailty(37). 310 
The role of testosterone in neuromuscular function has largely been investigated 311 
in the context of its effects on muscle mass. In both animal and human studies, 312 
testosterone has been shown to increase skeletal muscle size by, in part, increasing the 313 
number of muscle satellite cells to support muscle fiber hypertrophy(38).  314 
There is a paucity of research into the role of testosterone in motor unit health 315 
and remodelling processes. Available evidence comes from animal models of motor 316 
neuron injury. Byers et al, in an experimental model of spinal cord injury, found that 317 
testosterone treatment of female rats prevented atrophy of motor neuron dendrites and 318 
muscle fibers(16). Similarly, castration of adult male rodents led to motor neuron atrophy 319 
which was, almost completely, reverted by testosterone administration(14,15). In other 320 
rodent studies, exogenous testosterone accelerated regeneration of injured facial and 321 
sciatic nerves(17,18,39).  322 
The effects of testosterone are not uniform across the nervous system owing to 323 
reduced expression of androgen receptors in typical somatic motor neurons, such as 324 
those of the quadriceps, compared to the cranial motor neurons. Nonetheless, rodent 325 
research data suggest that testosterone has a neuroprotective role in the L2 spinal 326 
segment(40–42). 327 
Gonadal hormones regulate the brain-derived neurotrophic factor (BDNF) 328 
receptor, trkB(43). Work by Osborne suggests androgen-mediated expression of the 329 
BDNF receptor could help maintain motor neurons(41). 330 
 In humans, an age-related decline in testosterone levels has been linked to the 331 
loss of muscle mass and sarcopenia; interestingly, the magnitude of a concomitant decline 332 
in muscle strength and neuromuscular coordination appears to be far greater than 333 
expected from the degree of the muscle mass loss only(44).  334 
Similarly, testosterone-induced muscle hypertrophy in healthy older men does 335 
not necessarily translate into significant gains in muscle function and improved physical 336 
performance, raising questions about the previously unexplored role of testosterone in 337 
neuronal control of muscle function.  338 
We showed that low free testosterone, which is a biologically active fraction of 339 
circulating testosterone, is associated with impaired muscle electrophysiology assessed 340 
by maximal CMAP. The maximal CMAP size, whilst not dependant on total size of larger 341 
muscle groups(7) depends on the volume of contractile material within the recording 342 
range of the electrodes, and is proportional to the total size of the motor units activated 343 




subcutaneous fat thickness which did not differ here, as we and others have previously 345 
reported (7,45). Smaller CMAPs in older age have been reported for a number of 346 
muscles(46). In clinical practice, the CMAP remains a useful parameter to monitor 347 
progression of neuromuscular disorders such as motor neuron disease(34). Interestingly, 348 
the relationship of free T with CMAP size was greater with increasing levels of frailty. 349 
Although this is an observational study that cannot determine causality, the differing 350 
relationships by frailty status, could lead us to speculate that testosterone 351 
supplementation might improve neuromuscular function to a greater extent in frail rather 352 
than non-frail elderly populations. This idea is largely in keeping with the results of 353 
Testosterone Trials in which testosterone replacement in relatively healthy men resulted 354 
in very small gains in objectively-assessed and self-perceived physical function(47–50).  355 
Contrary to the relationship with CMAP, there was no observed relationship 356 
between T and MUP size, which may be explained by the non-linear trajectory of MUP size 357 
with increasing age. Expansion of the MU occurs as a compensatory process to minimise 358 
fibre loss, via reinnervation of denervated fibres, and a failure of this process contributes 359 
to sarcopenia, evidenced by larger MUPs in healthy old when compared to young, which 360 
are smaller again in older people with sarcopenia(12). It is therefore apparent that MUP 361 
size increases up to a certain ill-defined point when reinnervation is out-paced by 362 
denervation, fails to expand and proceeds to become smaller. 363 
 Our findings suggest that vitamin D may play a role in successful reinnervation 364 
occurring with ageing as evidenced by association of low vitamin D with smaller motor 365 
unit potentials. Adjusting for BMI attenuated the relationship between vitamin D and MUP 366 
size, and whilst we might have been underpowered to detect significant associations on 367 
multiple adjustments, the unadjusted model might still provide valuable insights into 368 
mechanisms linking vitamin D and sarcopenia. For example, it is possible that BMI is on 369 
the causal pathway linking vitamin D with MUP size, which could explain the effect of 370 
statistical adjustment.  371 
In experimental models, treatment with vitamin D has been shown to induce 372 
nerve growth factor synthesis (involved in peripheral nerve recovery post injury), reduce 373 
demyelination and induce axonal regeneration in a spinal cord compression and peroneal 374 
nerve injury model(51–53). Certainly the evidence from randomized placebo-controlled 375 
trials suggests that vitamin D replacement not only results in improved lower limb muscle 376 
mass and strength but also neuromuscular control and balance(54),(55).  377 
Whereas some of the effects of vitamin D deficiency on muscle are thought to be, 378 
in part, mediated by raised pro-inflammatory cytokines levels(26,56) and direct 379 




to altered muscle innervation(59) which is further supported by our findings . 381 
 382 
Strengths and limitations 383 
Our study has a number of strengths. Our cohort is representative of older community-384 
dwelling men and although the sample size may appear small, it is relatively large for an 385 
invasive study in elderly and frail participants. To our knowledge, it is the first study in 386 
humans to relate hormone levels to motor unit size and muscle electrophysiological 387 
characteristics assessed by intramuscular and surface electromyography. However, we 388 
did not measure calcium or PTH levels which may have helped in the interpretation of the 389 
vitamin D data. We have also not performed nerve conduction studies, which could have 390 
helped in the interpretation of study findings to identify whether deficits exist in motor 391 
neuron axons. Our work was limited to men, so the generalizability to women is unknown.  392 
 393 
Clinical and research implications 394 
Interventions preventing age-related motor unit loss are largely unknown. We have 395 
previously shown that even lifelong exercise does not attenuate this process and the 396 
muscles of master athletes show a similar loss to those of normally-active older men, 397 
however the older athletes appear to be more successful at reinnervation(13,60). The 398 
associations of free testosterone and vitamin D with neuromuscular parameters suggest 399 
that both hormones might contribute to preservation of muscle fibers and successful 400 
reinnervation.  401 
Whether intervention with these anabolic hormones could prevent motor unit 402 
loss or improves reinnervation remains unclear.  We recommend additional in vivo 403 
studies and clinical trials before there is any change in clinical practice. Testosterone 404 
replacement in frail hypogonadal men resulted in improvements in physical function but 405 
larger trials in this group of people are lacking(61). Moreover, the greater significance of 406 
relationships in frailer men suggests that hormonal manipulation aimed at improving 407 
muscle function might be of particular benefit in the frail.  408 
 409 
In conclusion, we have shown that testosterone was positively associated with the volume 410 
of excitable muscle tissue as assessed by CMAP.  We have also shown, in univariate 411 
analysis, that vitamin D was related to motor unit size. These cross-sectional hypothesis 412 
generating data suggest that it may be appropriate to design clinical trials to assess the 413 





 Figure Legends: 416 
 417 
Figure 1. Adjusted prediction of CMAP by free testosterone and frailty phenotype. 418 
Figure 2. Adjusted probability of CMAP by free testosterone and frailty index. 419 
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